FDA’s Sentinel project could function as an important comparator control for potential drug safety events already being investigated by the agency, FDA’s Robert Temple said during a public workshop on Sentinel sponsored by the Brookings Institution Jan. 18. Sentinel is an initiative the agency is developing to monitor postmarket drug safety events.
Temple, who is deputy center director for clinical science in the Center for Drug Evaluation and Research, characterized Sentinel as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?